These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 34875337)
1. Phosphodiesterase (PDE) 5 inhibitors sildenafil, tadalafil and vardenafil impact cAMP-specific PDE8 isoforms-linked second messengers and steroid production in a mouse Leydig tumor cell line. Limoncella S; Lazzaretti C; Paradiso E; D'Alessandro S; Barbagallo F; Pacifico S; Guerrini R; Tagliavini S; Trenti T; Santi D; Simoni M; Sola M; Di Rocco G; Casarini L Mol Cell Endocrinol; 2022 Feb; 542():111527. PubMed ID: 34875337 [TBL] [Abstract][Full Text] [Related]
2. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. Teixeira CE; Priviero FB; Webb RC J Pharmacol Exp Ther; 2006 Feb; 316(2):654-61. PubMed ID: 16204472 [TBL] [Abstract][Full Text] [Related]
3. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects. Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324 [TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update. Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034 [TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity. Zoraghi R; Corbin JD; Francis SH J Biol Chem; 2006 Mar; 281(9):5553-8. PubMed ID: 16407275 [TBL] [Abstract][Full Text] [Related]
6. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway. Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179 [TBL] [Abstract][Full Text] [Related]
7. In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach. Gratzke C; Uckert S; Kedia G; Reich O; Schlenker B; Seitz M; Becker AJ; Stief CG Urol Res; 2007 Feb; 35(1):49-54. PubMed ID: 17102958 [TBL] [Abstract][Full Text] [Related]
8. Repurposing PDE5 inhibitor tadalafil and sildenafil as anticancer agent against hepatocellular carcinoma via targeting key events of glucose metabolism and multidrug resistance. Chhonker SK; Rawat D; Koiri RK J Biochem Mol Toxicol; 2022 Aug; 36(8):e23100. PubMed ID: 35608386 [TBL] [Abstract][Full Text] [Related]
9. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Blount MA; Beasley A; Zoraghi R; Sekhar KR; Bessay EP; Francis SH; Corbin JD Mol Pharmacol; 2004 Jul; 66(1):144-52. PubMed ID: 15213306 [TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase type 5 inhibitors facilitate noncontact erections in male rats: site of action in the brain and mechanism of action. Sanna F; Succu S; Boi A; Melis MR; Argiolas A J Sex Med; 2009 Oct; 6(10):2680-9. PubMed ID: 19678884 [TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil. Kim E; Seftel A; Goldfischer E; Baygani S; Burns P Curr Med Res Opin; 2015 Feb; 31(2):379-89. PubMed ID: 25455432 [TBL] [Abstract][Full Text] [Related]
12. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Saenz de Tejada I; Angulo J; Cuevas P; Fernández A; Moncada I; Allona A; Lledó E; Körschen HG; Niewöhner U; Haning H; Pages E; Bischoff E Int J Impot Res; 2001 Oct; 13(5):282-90. PubMed ID: 11890515 [TBL] [Abstract][Full Text] [Related]
13. PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter. Chen JJ; Sun YL; Tiwari AK; Xiao ZJ; Sodani K; Yang DH; Vispute SG; Jiang WQ; Chen SD; Chen ZS Cancer Sci; 2012 Aug; 103(8):1531-7. PubMed ID: 22578167 [TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on esophageal motility: a systematic review. Shafiee A; Bahri RA; Teymouri Athar MM; Afsharrezaei F; Gholami M BMC Gastroenterol; 2023 May; 23(1):170. PubMed ID: 37217851 [TBL] [Abstract][Full Text] [Related]
15. Exposure to phosphodiesterase type 5 inhibitors stimulates aromatase expression in human adipocytes in vitro. Aversa A; Caprio M; Antelmi A; Armani A; Brama M; Greco EA; Francomano D; Calanchini M; Spera G; Di Luigi L; Rosano GM; Lenzi A; Migliaccio S; Fabbri A J Sex Med; 2011 Mar; 8(3):696-704. PubMed ID: 21176111 [TBL] [Abstract][Full Text] [Related]
16. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. Jannini EA; Isidori AM; Gravina GL; Aversa A; Balercia G; Bocchio M; Boscaro M; Carani C; Corona G; Fabbri A; Foresta C; Forti G; Francavilla S; Granata AR; Maggi M; Mansani R; Palego P; Spera G; Vetri M; Lenzi A; J Sex Med; 2009 Sep; 6(9):2547-60. PubMed ID: 19570039 [TBL] [Abstract][Full Text] [Related]
17. Modulation of high affinity ATP-dependent cyclic nucleotide transporters by specific and non-specific cyclic nucleotide phosphodiesterase inhibitors. Aronsen L; Orvoll E; Lysaa R; Ravna AW; Sager G Eur J Pharmacol; 2014 Dec; 745():249-53. PubMed ID: 25445042 [TBL] [Abstract][Full Text] [Related]
18. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Sarfati M; Mateo V; Baudet S; Rubio M; Fernandez C; Davi F; Binet JL; Delic J; Merle-Beral H Blood; 2003 Jan; 101(1):265-9. PubMed ID: 12393651 [TBL] [Abstract][Full Text] [Related]
19. Testosterone/estradiol ratio regulates NO-induced bladder relaxation and responsiveness to PDE5 inhibitors. Vignozzi L; Filippi S; Morelli A; Comeglio P; Cellai I; Sarchielli E; Maneschi E; Mancina R; Gacci M; Vannelli GB; Maggi M J Sex Med; 2012 Dec; 9(12):3028-40. PubMed ID: 23057807 [TBL] [Abstract][Full Text] [Related]
20. Sildenafil treatment in vivo stimulates Leydig cell steroidogenesis via the cAMP/cGMP signaling pathway. Andric SA; Janjic MM; Stojkov NJ; Kostic TS Am J Physiol Endocrinol Metab; 2010 Oct; 299(4):E544-50. PubMed ID: 20663985 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]